Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Survival after invasive coronary revascularization is worse in patients with chronic kidney
disease than in those without it. The investigators aimed to examine whether oral
administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive
potassium channel opener, could improve the survival of end-stage renal disease patients with
coronary artery disease by inhibiting cardiac death after coronary revascularization.